Mission Statement, Vision, & Core Values (2024) of Hansoh Pharmaceutical Group Company Limited

A Brief History of Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited, founded in 1995 and headquartered in Jiangsu, China, has established itself as a prominent player in the life sciences sector. Over the years, the company has focused on the research, development, manufacturing, and marketing of a range of pharmaceutical products, with a particular emphasis on oncology, neuropsychiatry, and anti-infective therapies.

In 2019, Hansoh Pharmaceutical made a significant leap when it went public on the Hong Kong Stock Exchange, raising approximately HKD 3.69 billion (approximately USD 470 million) through its initial public offering (IPO). This event marked a critical milestone in the company’s evolution and provided capital to fuel its extensive R&D efforts.

As of 2023, Hansoh Pharmaceutical has recorded remarkable growth metrics. In its most recent earnings report for the first half of 2023, the company reported:

• Revenue of RMB 5.56 billion (approximately USD 850 million)
• Net profit of RMB 1.52 billion (approximately USD 230 million)
• Gross margin of 70%

Hansoh's diverse portfolio includes over 100 pharmaceutical products that cater to various therapeutic areas. The company has also engaged in strategic collaborations and partnerships with other global pharmaceutical firms to enrich its product pipeline. As of 2023, Hansoh boasts a pipeline of over 20 innovative drug candidates in various stages of clinical trials.

In addition, Hansoh continues to invest heavily in R&D. The company allocated approximately RMB 1.1 billion (around USD 170 million) for R&D expenses in the first half of 2023, reflecting a commitment of about 19.8% of its total revenue. This focus on innovation has allowed Hansoh to bring products to market quickly, responding to growing healthcare demands.

The pharmaceutical landscape in China is highly competitive, and Hansoh Pharmaceutical has been positioning itself through organic growth and strategic acquisitions. In 2022, Hansoh acquired a leading biotech firm, enhancing its capabilities in biologics, which significantly contributes to its long-term growth objectives and strategic vision.

As of September 2023, Hansoh Pharmaceutical is recognized among the top pharmaceutical companies in China, boasting a market capitalization of approximately USD 15 billion. The company's stock performance has shown resilience, reflecting broader trends in the healthcare sector.

A Who Owns Hansoh Pharmaceutical Group Company Limited

As of the latest reports, Hansoh Pharmaceutical Group Company Limited is primarily owned by a combination of institutional and individual investors, alongside key executives. The company went public on the Hong Kong Stock Exchange under the ticker symbol 3689.HK in June 2019.

The following table summarizes the major shareholders of Hansoh Pharmaceutical as of the most recent disclosures:

The ownership structure indicates that Jiangsu Hansoh Pharmaceutical Group Co. Ltd. retains substantial control over the company, reflecting a strong founding presence. Institutional investors follow closely and contribute significantly to corporate governance through their holdings.

According to the company's financial reports, as of the second quarter of 2023, Hansoh Pharmaceutical reported a revenue of approximately RMB 3.1 billion ($470 million), marking a year-over-year increase of 14.5%. The company's net profit for the same period was approximately RMB 690 million ($105 million), indicating a net profit margin of about 22.3%.

The stock performance of Hansoh Pharmaceutical has shown fluctuations since its IPO. Initially priced at HKD 34.0 per share, the stock has ranged from a low of HKD 20.0 to a high of HKD 55.0. As of the close on October 20, 2023, the stock was trading at HKD 42.7, reflecting a market capitalization of approximately HKD 134 billion ($17 billion).

The shareholding structure and financial performance of Hansoh Pharmaceutical emphasize its competitive position within the pharmaceutical industry, supported by a strong leadership team and substantial institutional backing.

Hansoh Pharmaceutical Group Company Limited Mission Statement

Hansoh Pharmaceutical Group Company Limited aims to be a leading biopharmaceutical company. Their mission emphasizes innovation, quality, and accessibility in healthcare. The company focuses on developing, manufacturing, and marketing a broad range of medications to address unmet medical needs across the globe.

According to the latest data, Hansoh Pharmaceutical has committed to investing over 10% of its annual revenue into research and development (R&D). The company reported an R&D expenditure of approximately RMB 1.58 billion in 2022, reflecting its dedication to innovation.

The corporate strategy encompasses three key components:

• Focus on patient needs by developing advanced therapies.
• Maintain high-quality manufacturing processes to ensure the safety and efficacy of their products.
• Expand their market reach, particularly in Asia and emerging economies.

In 2022, Hansoh Pharmaceutical's revenue was RMB 8.06 billion, with a year-over-year growth rate of 29.3%. The international market contributed significantly, accounting for approximately 22% of total revenue.

Financial Overview

The company’s strategic initiatives have led to a compound annual growth rate (CAGR) of approximately 32% in revenue over the past three years. Hansoh has also successfully registered over 50 new drug applications in China and abroad, underpinning its commitment to expanding its product portfolio.

In terms of employee engagement, Hansoh Pharmaceutical values its workforce, boasting an employee satisfaction rate of 87% based on the latest internal surveys. This commitment to personnel welfare is reflected in a 10% increase in headcount year-over-year, reaching over 5,500 employees as of 2023.

The company's mission statement not only defines its operational goals but also reflects its commitment to corporate social responsibility, focusing on sustainable practices and community health initiatives. For instance, Hansoh has pledged to invest over RMB 200 million in public health programs over the next five years.

Hansoh Pharmaceutical continues to adapt its strategies to align with global healthcare trends, emphasizing its role in delivering essential pharmaceutical solutions while maintaining high standards of quality and innovation.

How Hansoh Pharmaceutical Group Company Limited Works

Hansoh Pharmaceutical Group Company Limited, listed on the Hong Kong Stock Exchange under the ticker symbol H11717, is a leading Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs. Established in 1995, Hansoh targets major therapeutic areas such as oncology, central nervous system disorders, and infectious diseases.

As of the end of 2022, Hansoh reported total revenue of approximately RMB 5.16 billion, representing a growth rate of 25.2% year-over-year. The company’s net profit for the same period reached about RMB 1.13 billion, up from RMB 950 million in 2021.

Product Portfolio

The company boasts a diverse product portfolio including over 100 products, with approximately 50 approved drugs across various stages of the regulatory process. Among its prominent products are:

• HANSOH ZHENGFEN - A leading oncology drug for treatment of non-small cell lung cancer.
• HANSOH YUANFEN - A central nervous system agent for treating major depressive disorder.
• HANSOH JINHUI - An antidiabetic medication widely utilized in China.

Research and Development

Research and development (R&D) is a core focus for Hansoh, with an investment of RMB 1.05 billion in R&D for fiscal year 2022, representing approximately 20.3% of total revenue. The company has established multiple R&D centers, both domestically and internationally, allowing it to leverage global talent and innovation.

Manufacturing Capabilities

Hansoh operates several state-of-the-art manufacturing facilities, adhering to international quality standards. The production capacity has reached over 10 million units annually across various dosage forms, including tablets, injectables, and biologics.

Market Position

As of 2023, Hansoh is ranked among the top biopharmaceutical companies in China, holding a significant market share in the oncology and central nervous system sectors. The company’s strategic focus on innovative therapies positions it favorably within the competitive landscape.

International Expansion

Hansoh has been actively pursuing international collaborations and partnerships. In 2022, the company entered into a partnership with several global pharmaceutical firms aimed at co-developing and commercializing innovative therapies. Approximately 30% of its revenue is expected to derive from international markets by 2025.

Financial Stability

The company's financial health remains strong, reflected in its debt-to-equity ratio of 0.25 as of 2022, indicating a low level of financial leverage. Furthermore, the current ratio stands at 2.2, suggesting robust liquidity.

Hansoh is primed for continued growth fueled by its strong R&D pipeline, manufacturing capabilities, and expanding market presence.

How Hansoh Pharmaceutical Group Company Limited Makes Money

Hansoh Pharmaceutical Group Company Limited generates revenue through multiple streams, primarily focused on the development, manufacturing, and sale of innovative pharmaceutical products. The company operates in therapeutic areas such as oncology, central nervous system (CNS), and anti-infectives, contributing significantly to its income.

For the fiscal year 2022, Hansoh reported total revenue of approximately RMB 7.26 billion (about $1.08 billion), reflecting a year-on-year increase of 19.3%. This growth can be attributed to the strong demand for its key therapeutic products and an expanded market presence.

Revenue Breakdown by Product Categories

The revenue composition is critical for understanding how Hansoh earns its income. Below is a breakdown of the total revenue by therapeutic area for 2022:

Sales from oncology drugs represented approximately 41.3% of total revenue, marking it as Hansoh's largest revenue segment. The CNS segment, with a remarkable growth rate of 36.4%, indicates a growing market demand.

Strategic Partnerships and Collaborations

Hansoh has developed strategic partnerships with several international pharmaceutical companies, enabling it to enhance its research capabilities and expand its product offerings. For instance, it partnered with Janssen Pharmaceuticals to co-develop and market innovative drugs, which has significantly broadened its market reach and revenue potential.

Market Expansion and Sales Channels

The company has expanded its operations in both domestic and international markets. In 2022, Hansoh launched its products in more than 20 countries, with a focus on entering markets in Europe and North America. This international expansion aims to capture a larger share of the global pharmaceutical market.

Hansoh utilizes various sales channels to maximize revenue, including direct sales, distributors, and online platforms, allowing it to reach consumers efficiently. In 2022, online sales accounted for approximately 15% of total sales, a significant growth area reflecting changing consumer preferences.

Research and Development Investment

Investment in research and development (R&D) is crucial for Hansoh's long-term growth. In 2022, the company allocated RMB 1.2 billion (around $180 million) to R&D, representing about 16.5% of its total revenue. This strategic investment focuses on the development of novel drug formulations and ensuring a robust pipeline of future products.

Hansoh's commitment to innovation has resulted in a strong portfolio of over 20 products under development, with several candidates in late-stage clinical trials. The company aims to introduce new products to market, thereby enhancing its competitive edge.

Financial Performance and Stock Trends

As of September 2023, Hansoh's stock performance has also been noteworthy. The stock price reflected a year-to-date increase of approximately 25%, positioning it favorably within the competitive landscape of pharmaceutical stocks listed on the Hong Kong Stock Exchange (stock code: 3692). The company maintains a market capitalization of around RMB 50 billion (about $7.5 billion).

Overall, Hansoh Pharmaceutical Group Company Limited continues to leverage its extensive product portfolio, strategic partnerships, and significant R&D investment to drive revenue growth and enhance shareholder value.